HER2 and ABCC1 are identified as significant transcriptomic predictors of overall survival in patients treated with T-DXd. A large-scale analysis reveals novel predictors of survival and resistance ...
Researchers have revealed how patients with metastatic breast cancer develop resistance to Enhertu treatment.
Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ...
BriaCell patients treated since 2022 remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard ...
Greenwich's $3.81 million cash position covers less than two months of operations, making near-term financing highly likely ...
Daiichi Sankyo & AstraZeneca’s Enhertu approved in China as first and only HER2 directed ADC for second-line treatment of patients with HER2 positive metastatic gastric cancer ...
Brazilian researchers have identified previously unknown forms of a protein linked to breast cancer. The discovery ...
At the San Antonio Breast Cancer Symposium, researchers discussed how results from HER2CLIMB-05 may inform first-line ...
EMA validates Enhertu plus pertuzumab type II variation application in EU as first-line treatment of patients with HER2 positive metastatic breast cancer: Tokyo Tuesday, January 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results